EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lymphoid and CXCR4 Cell Targeted Lipid Nanoparticles Facilitate HIV‐1 Proviral DNA Excision

Sudipta Panja, Lubaba A Zaman, Chen Zhang, Milankumar Patel, Santhi Gorantla, Prasanta K Dash, Howard E Gendelman iD

Advanced Healthcare Materials · 2025-09 · 14 (25)

DOI: 10.1002/adhm.202501190 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 14.07.2025. Verfasst von Sudipta Panja und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA. Hauptthemen laut MEDLINE: Receptors, CXCR4, HIV-1, Nanoparticles, DNA, Viral. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIH HHS, NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advancements in antiretroviral therapy (ART) enable those living with the human immunodeficiency virus type one (HIV‐1) to lead longer, healthier lives free from disease comorbidities. However, lifelong ART poses challenges. These include social stigma, medication costs, drug accessibility, mental health, and drug‐related toxicities. Moreover, ART does not eliminate latent HIV‐1 DNA. Viral persistence in tissue and cell reservoirs results in viral rebound after ART interruption. New strategies are required to achieve a functional HIV‐1 cure. To excise latent HIV‐1, C‐X‐C motif chemokine receptor 4 (CXCR4) ligand‐decorated lymphoid tissue‐targeting lipid nanoparticles (LNPs) for CRISPR‐Cas9/gRNA delivery are developed. These LNPs enhance mRNA translation and demonstrate CXCR4‐mediated improved uptake to eliminate HIV‐1 DNA in infected CD4+ T cells. LNPs also facilitate targeted drug delivery, achieving HIV‐1 DNA excision in ART‐treated, infected humanized mice. This study emphasizes the potential of tissue and cell‐targeted LNPs for effective HIV‐1 DNA excision.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CXCR4HIV-1NanoparticlesDNA, ViralLipidsProvirusesHumansAnimalsMiceHIV InfectionsCD4-Positive T-LymphocytesLiposomes

Stichwörter der Autor:innen

CRISPRHIV‐1 infectionexcision of HIV‐1 DNAlipid nanoparticlestargeted mRNA delivery

Substanzen

Receptors, CXCR4DNA, ViralLipidsCXCR4 protein, humanLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA.

ORCID-Profile: Howard E Gendelman

Förderung

  • NINDS NIH HHS
  • NIH HHS
  • NIMH NIH HHS
  • NIDA NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • National Institute of Neurological Disorders and Stroke
  • National Institute of Mental Health

Zitieren

APA

Panja, S., Zaman, L. A., Zhang, C., Patel, M., Gorantla, S., Dash, P. K., & Gendelman, H. E. (2025). Lymphoid and CXCR4 Cell Targeted Lipid Nanoparticles Facilitate HIV‐1 Proviral DNA Excision. Advanced Healthcare Materials, 14(25). https://doi.org/10.1002/adhm.202501190

Vancouver

Panja S, Zaman LA, Zhang C, Patel M, Gorantla S, Dash PK, et al. Lymphoid and CXCR4 Cell Targeted Lipid Nanoparticles Facilitate HIV‐1 Proviral DNA Excision. Advanced Healthcare Materials. 2025;14(25). doi:10.1002/adhm.202501190

BibTeX
@article{Panja2025,
  author = {Panja, Sudipta and Zaman, Lubaba A and Zhang, Chen and Patel, Milankumar and Gorantla, Santhi and Dash, Prasanta K and Gendelman, Howard E},
  title = {Lymphoid and CXCR4 Cell Targeted Lipid Nanoparticles Facilitate HIV‐1 Proviral DNA Excision},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  volume = {14},
  number = {25},
  doi = {10.1002/adhm.202501190}
}
Kostenlos starten →